These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3624101)

  • 21. Medical devices; investigational device exemptions--FDA. Final rule.
    Fed Regist; 1998 Nov; 63(225):64617-26. PubMed ID: 10338870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trials and tribulations: a primer on successfully navigating the waters of the Food and Drug Administration.
    Feinsod M; Chambers WA
    Ophthalmology; 2004 Oct; 111(10):1801-6. PubMed ID: 15465539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigational new drug applications; clinical holds; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Dec; 63(239):68710-2. PubMed ID: 10187560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective.
    Schwieterman WD
    Drug Discov Today; 2006 Oct; 11(19-20):945-51. PubMed ID: 16997146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical devices; investigational device exemptions--FDA. Proposed rule.
    Fed Regist; 1998 Jul; 63(135):38131-8. PubMed ID: 10181246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory aspects of investigational new drugs.
    Arbit HM
    Am J Hosp Pharm; 1978 Jan; 35(1):81-5. PubMed ID: 341700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current good manufacturing practice regulation and investigational new drugs. Direct final rule.
    Food and Drug Administration. HHS
    Fed Regist; 2006 Jan; 71(10):2458-62. PubMed ID: 16479693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical devices; procedures for investigational device exemptions--Food and Drug Administration. Final rule.
    Fed Regist; 1980 Jan; 45(13):3732-59. PubMed ID: 10248822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advisory committees; OTC Drugs Advisory Committee; establishment--FDA. Final rule.
    Fed Regist; 1991 Sep; 56(185):48103-4. PubMed ID: 10114368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conforming regulations regarding removal of section 507 of the Federal Food, Drug, and Cosmetic Act; confirmation of effective date. Food and Drug Administration, HHS. Direct final rule; confirmation of effective date.
    Fed Regist; 1999 May; 64(94):26657. PubMed ID: 10558515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delegations of authority and organization; Center for Drug Evaluation and Research--FDA. Final rule.
    Fed Regist; 1993 Apr; 58(61):17093-4. PubMed ID: 10125229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of the FDA in the effort against AIDS.
    Young FE
    Public Health Rep; 1988; 103(3):242-5. PubMed ID: 3131814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigator responsibilities for clinical research studies: proper staffing can ensure an investigator is compliant.
    Kee AN
    J Med Pract Manage; 2011; 26(4):245-7. PubMed ID: 21506468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigational new drug, antibiotic, and biological product applications; clinical hold and termination--FDA. Final rule.
    Fed Regist; 1992 Apr; 57(73):13244-9. PubMed ID: 10118458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns.
    Goldman SA
    Drug Saf; 2016 Oct; 39(10):895-901. PubMed ID: 27473417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trials in molecular imaging: the importance of following the protocol.
    Trembath L; Opanowski A;
    J Nucl Med Technol; 2011 Jun; 39(2):63-9. PubMed ID: 21565960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obtaining drugs from foreign markets.
    Shirk MB; Hale KN
    Am J Hosp Pharm; 1992 Nov; 49(11):2731-9. PubMed ID: 1471638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
    Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
    Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current good manufacturing practice for positron emission tomography drugs.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Dec; 74(236):65409-36. PubMed ID: 20169678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.